RxDoctor Payments Data

Masood Ahmed, MD

Interventional Cardiology · Newport News, VANPI 1093796310

Payments from drug & device makers

$2,612in general payments, 2019–2025

Across 144 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$477
  • Johnson & Johnson$347
  • Amgen$320
  • AstraZeneca$260
  • Sanofi-aventis U.S. LLC$224
  • Philips North America LLC$160
  • plus $824 from 16 others

What the payments were for

  • Food & beverage$2,55498%
  • Education$582%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,612 in reported general payments places this provider in the 30th percentile of 176 interventional cardiology providers in Virginia.

See all interventional cardiology providers in Virginia

Medicare billing

Part B allowed, 2024
$495,368
Medicare patients
1,091
Services billed
5,197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban311$304,190
XareltoRivaroxaban118$127,862
EntrestoSacubitril/Valsartan48$51,671
MultaqDronedarone Hcl28$45,962
BrilintaTicagrelor71$35,433
FarxigaDapagliflozin Propanediol27$26,014
Repatha SureclickEvolocumab25$18,725
Praluent PenAlirocumab11$5,663
Metoprolol Succinate482$4,529
Diltiazem 24hr Er (Cd)Diltiazem Hcl122$2,815
Amiodarone Hcl62$2,358
Flecainide Acetate44$1,600
Ranolazine ErRanolazine23$1,374
Dilt-XrDiltiazem Hcl31$1,312
Midodrine Hcl19$1,198

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$59$304,190311 claims
Johnson & JohnsonXarelto$347$127,862118 claims
AstraZenecaBrilinta, Farxiga$260$61,44898 claims
NovartisEntresto$57$51,67148 claims
Sanofi-aventis U.S. LLCMultaq$224$45,96228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 176 interventional cardiology providers in Virginia.

Other interventional cardiology in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →